Corologic, a cardiovascular AI startup, has raised seed funding from Kakao Ventures and SNU Holdings for its AngioFilm solution, which reduces radiation exposure during coronary angiography by up to 50%. The company plans to accelerate commercialization with multicenter clinical validation and regulatory approvals.
TL;DR
- Corologic raises seed funding for AngioFilm, an AI solution that reduces radiation exposure during coronary angiography by up to 50%.
- The funding will support multicenter clinical validation and regulatory approvals, accelerating commercialization.
- AngioFilm uses AI-based video frame interpolation to restore low frame rate footage into high-frame-rate video in real time, reducing the number of X-ray images captured.
What happened
Corologic, a cardiovascular imaging AI startup, announced on the 15th that it has secured seed funding from Kakao Ventures and SNU Holdings. The company was founded in May 2026 by a team led by Professor Kang Si-hyuk of the division of cardiology at Seoul National University Bundang Hospital.
AngioFilm, Corologic's AI solution, is designed to reduce radiation exposure for both patients and medical staff during coronary angiography. The technology uses AI-based video frame interpolation (VFI) to restore angiography footage shot at a low frame rate into what appears to be high-frame-rate video in real time.
The AI analyzes the position and movement of blood vessels and medical devices in the preceding and following frames of a continuous image sequence, then estimates the intermediate view to generate a new frame. This allows medical staff to follow vessel movement and the course of the procedure without interruption while reducing the number of X-ray images captured.
AngioFilm can be linked to existing angiography equipment and processes images in real time within the hospital using an edge approach. The company has already presented related research findings at EuroPCR 2026 and completed a medical device filing with the Ministry of Food and Drug Safety in August.
Why it matters
The funding will enable Corologic to pursue multicenter clinical validation and regulatory approvals, both domestically and internationally, accelerating the commercialization of AngioFilm. This is a significant step for the startup as it seeks to expand its market reach.
For developers and startups in the AI and medical imaging space, Corologic's AngioFilm demonstrates the potential of AI-based solutions to improve patient and medical staff safety. The technology's compatibility with existing equipment and its edge processing capabilities make it a promising innovation.
Investors will be watching Corologic's progress closely, as the company aims to secure broader approvals from the drug safety ministry, a U.S. Food and Drug Administration 510(k) clearance, and ISO 13485 global quality certification. The potential for global market expansion makes this a compelling investment opportunity.
Key facts
- Corologic raised seed funding from Kakao Ventures and SNU Holdings.
- AngioFilm reduces radiation exposure during coronary angiography by up to 50%.
- The AI solution uses video frame interpolation to restore low frame rate footage into high-frame-rate video in real time.
- AngioFilm can be linked to existing angiography equipment and processes images in real time within the hospital.
- Corologic presented research findings at EuroPCR 2026 and completed a medical device filing with the Ministry of Food and Drug Safety in August.
- The company plans to pursue multicenter clinical validation and regulatory approvals, including U.S. FDA 510(k) clearance and ISO 13485 certification.
- Corologic was founded in May 2026 by a team led by Professor Kang Si-hyuk of Seoul National University Bundang Hospital.
- Kakao Ventures sees potential for global market expansion due to AngioFilm's standalone solution approach.
Context
Cardiovascular interventions such as coronary angiography are performed while viewing X-ray fluoroscopic images, which exposes both patients and medical staff to radiation. This is an area that needs technological solutions to improve safety.
AI-based solutions like AngioFilm have the potential to revolutionize medical imaging by reducing radiation exposure while maintaining image quality. The technology's compatibility with existing equipment and its edge processing capabilities make it a promising innovation in the field.
Corologic's AngioFilm is part of a growing trend of AI applications in healthcare, aimed at improving patient outcomes and enhancing the efficiency of medical procedures. As the company advances product development and clinical validation, it is poised to make a significant impact in the cardiovascular intervention space.